Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropneia in patients with hematological malignancies

Akihito ShinoharaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Yumiko YoshikiDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Yosuke MasamotoDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Akira HangaishiDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Yasuhito NannyaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, JapanCorrespondence[email protected]

Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropneia in patients with hematological malignancies

Supplementary Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Moxifloxacin is more effective than tosufloxacin in reducing chemotherapy-induced febrile neutropneia in patients with hematological malignancies

Supplementary Material

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date